CF101

Phase 3Small molecule

CCan-Fite BioPharma

CF101 is one of 167 small molecule programs targeting Eye Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

166

Competitors

Pipeline

Status by Indication[3][1]

Indication

Eye DiseaseActive, not recruiting

Keratoconjunctivitis SiccaActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

PsoriasisActive, not recruiting

OsteoarthritisActive, not recruiting

UveitisActive, not recruiting

Eye DiseasePhase 3

Active, not recruiting

Keratoconjunctivitis SiccaPhase 2

Active, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

PsoriasisPhase 2/Phase 3

Active, not recruiting

OsteoarthritisPhase 2

Active, not recruiting

UveitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

CF101

CCan-Fite BioPharma

Phase 3

4 2

Rituxan

Roche

Preclinical

61 3

Orencia

Bristol-Myers Squibb

Preclinical

47 4

Cimzia

UCB

Preclinical

30 5

Simponi

Johnson & Johnson

Preclinical

19 6

Remicade

OOrganon and Co

Preclinical

43 7

Arcoxia

Novartis

Preclinical

4 8

Actos

Takeda

Preclinical

2 9

Celexa

AbbVie

Preclinical

1 10

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis4 trials

Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis

Completed·CCan-Fite BioPharma·Phase 2·NCT01034306·79 enrolled

Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients

Completed·CCan-Fite BioPharma·Phase 2·NCT00556894·253 enrolled

CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis

Terminated·CCan-Fite BioPharma·Phase 3·NCT02647762·244 enrolled

Show 1 more trial

Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients

Completed·CCan-Fite BioPharma·Phase 2·NCT00280917·254 enrolled

Psoriasis3 trials

Safety and Efficacy Study of CF101 to Treat Psoriasis

Completed·CCan-Fite BioPharma·Phase 2·NCT00428974·76 enrolled

CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis

Completed·CCan-Fite BioPharma·Phase 3·NCT03168256·528 enrolled

Trial of CF101 to Treat Patients With Psoriasis

Completed·CCan-Fite BioPharma·Phase 2/3·NCT01265667·293 enrolled

Uveitis1 trial

Safety &Efficacy of CF101 to Subjects With Uveitis

Withdrawn·CCan-Fite BioPharma·Phase 2·NCT01905124

Eye Disease1 trial

Trial of CF101 to Treat Patients With Dry Eye Disease

Completed·CCan-Fite BioPharma·Phase 3·NCT01235234·236 enrolled

Keratoconjunctivitis sicca1 trial

Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca

Completed·CCan-Fite BioPharma·Phase 2·NCT00349466·80 enrolled

2 more indications

Intraocular Pressure1 trial

Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure

Completed·CCan-Fite BioPharma·Phase 2·NCT01033422·89 enrolled

Osteoarthritis1 trial

A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee

Withdrawn·CCan-Fite BioPharma·Phase 2·NCT00837291

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for CF101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CF101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CF101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Can-Fite BioPharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCan-Fite BioPharma

CF101

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis4 trials

Psoriasis3 trials

Uveitis1 trial

Eye Disease1 trial

Keratoconjunctivitis sicca1 trial

Intraocular Pressure1 trial

Osteoarthritis1 trial

References

Drug Info

Quick Facts

Related News